Hypoxia-inducible factors in the kidney

Volker H. Haase

Renal Electrolyte and Hypertension Division, Department of Medicine,
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Haase, Volker H. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol 291: F271–F281, 2006; doi:10.1152/ajprenal.00071.2006.—Tissue hypoxia not only occurs under pathological conditions but is also an important microenvironmental factor that is critical for normal embryonic development. Hypoxia-inducible factors HIF-1 and HIF-2 are oxygen-sensitive basic helix-loop-helix transcription factors, which regulate biological processes that facilitate both oxygen delivery and cellular adaptation to oxygen deprivation. HIFs consist of an oxygen-sensitive α-subunit, HIF-α, and a constitutively expressed β-subunit, HIF-β, and regulate the expression of genes that are involved in energy metabolism, angiogenesis, erythropoiesis and iron metabolism, cell proliferation, apoptosis, and other biological processes. Under conditions of normal PO2, HIF-α is hydroxylated and targeted for rapid proteasomal degradation by the von Hippel-Lindau (VHL) E3-ubiquitin ligase. When cells experience hypoxia, HIF-α is stabilized and either dimerizes with HIF-β in the nucleus to form transcriptionally active HIF, executing the canonical hypoxia response, or it physically interacts with unrelated proteins, thereby enabling convergence of HIF oxygen sensing with other signaling pathways. In the normal, fully developed kidney, HIF-1α is expressed in most cell types, whereas HIF-2α is mainly found in renal interstitial fibroblast-like cells and endothelial cells. This review summarizes some of the most recent advances in the HIF field and discusses their relevance to renal development, normal kidney function and disease.

erythropoiesis; renal ischemia-reperfusion injury; renal fibrosis; renal cell cancer

OVERVIEW OF HIF SIGNALING

Tissue hypoxia, aside from being a frequently encountered clinical problem as a result of pulmonary or cardiovascular conditions, is also an important microenvironmental factor that is critical for the regulation of normal embryonic development and stem cell maintenance (1, 2, 21, 22, 86, 123, 140). Over the last decade, major advances have been made in deciphering the molecular mechanisms that allow cells to respond and to adapt to low PO2. As key mediators in cellular oxygen homeostasis, hypoxia-inducible factor-1 and -2 (HIF-1 and HIF-2) facilitate both oxygen delivery and adaptation to oxygen deprivation by regulating the expression of gene products that are involved in cellular energy metabolism and glucose transport, angiogenesis, erythropoiesis and iron metabolism, pH regulation, apoptosis, and cell proliferation as well as cell-cell and cell-matrix interactions (112, 136). Examples of classic HIF target genes are phosphoglycerate kinase-1 (PGK), glucose transporter-1 (GLUT1), vascular endothelial growth factor (VEGF), and erythropoietin (EPO) (for detailed reviews, see Refs. 112 and 136).

HIF-1 and HIF-2 (here collectively referred to as HIF) are members of the Per-ARNT-Sim (PAS) family of heterodimeric basic helix-loop-helix (bHLH) transcription factors and consist of an oxygen-sensitive α-subunit and a constitutively expressed β-unit, also known as the aryl hydrocarbon receptor nuclear translocator (ARNT) or simply HIF-β (112, 136). Direct transcriptional regulation occurs through the binding of HIF heterodimers to hypoxia-response elements (HREs), which are present in regulatory regions of hypoxia-sensitive genes (Fig. 1) (136). With regard to their ability to transcriptionally regulate specific hypoxia-responsive genes, HIF-1 and HIF-2 have distinct functions and only partially overlap. For example, glycolytic genes appear to be predominantly regulated by HIF-1 (50), whereas our group and others have suggested that HIF-2 is the main regulator of hypoxic VEGF and EPO induction in tissues that express both HIF-1 and HIF-2 (85, 93, 135). Oct-4, a transcription factor important in regulating stem cell fate, appears to be a specific HIF-2 target (21). Target gene selectivity between HIF-1 and HIF-2 may be the result of tissue-specific interactions with other nuclear factors, differential interactions with transcriptional cofactors, or be a reflection of tissue- and cell type-dependent differences in the ratios of HIF-α protein levels (for a recent review on this issue, see Ref. 104).

In addition to heterodimerization with HIF-β resulting in the formation of a bHLH transcription factor, which mediates the canonical hypoxia response, HIF-α subunits also regulate biological processes through direct protein-protein interaction with other factors. These include, among others, tumor suppressor protein p53 and the c-Myc protooncogene (67, 98). A more recent example is the ability of HIF-1α to biochemically associate with the intracellular domain of Notch (Notch ICD), thereby increasing Notch signaling through upregulation of Notch target genes, such as Hey and Hes (39). How HIF-α and Notch interact exactly and whether other cofactors are involved

Address for reprint requests and other correspondence: V. H. Haase, Dept. of Medicine, Univ. of Pennsylvania School of Medicine, 700 CRB, 415 Curie Blvd, Philadelphia, PA 19104-6144 (e-mail: vhaase@mail.med.upenn.edu).
Invited Review

F272

HIF IN KIDNEY FUNCTION

Fig. 1. Canonical and noncanonical hypoxic signaling through hypoxia-inducible factor (HIF). Under normoxia, hydroxylation of HIF-α-subunits by HIF prolyl-4-hydroxylases is required for binding to the pVHL-E3-ubiquitin ligase complex. After polyubiquitination, HIF-α is degraded by the proteasome. During hypoxia when prolyl-hydroxylases are inactive, HIF-α-subunit degradation is inhibited. HIF-α translocates to the nucleus, where it binds to HIF-β. HIF-α/β heterodimers then bind to the HIF-DNA consensus binding site, RCGTG, and increase transcription of HIF-target genes, e.g., erythropoietin (EPO), VEGF, and glucose transporter-1 (GLUT1). Factor-inhibiting HIF (FIH) is an asparagine (Asn) hydroxylase that modulates cofactor recruitment to the HIF transcriptional complex via asparagine hydroxylation of the HIF-α COOH-terminal transactivation domain. FIH activity is oxygen dependent. Noncanonical HIF signaling occurs through biochemical interaction with other proteins, such as the Notch intracellular domain (ICD; for a more complete overview of HIF-α-interaction with other proteins, see Ref. 136). Nitric oxide (NO), reactive oxygen species (ROS), the Krebs cycle metabolites succinate and fumarate, see Ref. 136). Nitric oxide (NO), reactive oxygen species (ROS), the Krebs cycle metabolites succinate and fumarate, as well as desferroxamine are known to inhibit HIF prolyl-4-hydroxylases in the presence of oxygen. PHI, prolyl-hydroxylase inhibitor; Pro, proline.

are presently unclear, but the observation that HIF-1α modulates Notch signaling through a direct protein-protein interaction underscores the importance of HIF-α as a regulator of important intracellular pathways, independent of its role in HRE-mediated transcription.

HIF activation is dependent on stabilization of the oxygen-sensitive α-subunit and its subsequent translocation to the nucleus, where it dimerizes with HIF-β and recruits transcriptional cofactors such as CBP and p300 (112, 136). Normally, under conditions of adequate oxygen supply, hydroxylated HIF-α binds to the von Hippel-Lindau tumor suppressor protein (pVHL), which is part of an E3-ubiquitin ligase complex that targets HIF-α for proteasomal degradation (Fig. 1). All three known HIF-α-subunits, i.e., HIF-1α, HIF-2α, and HIF-3α, have been shown to bind to pVHL (the role of HIF-3α in hypoxic signaling is unclear; a HIF-3α splice variant, IPAS, may be inhibitory) (75). The pVHL/HIF-α interaction is highly conserved between species and requires iron- and oxygen-dependent hydroxylation of specific proline residues (Pro402 and Pro564 in human HIF-1α; Pro405 and Pro531 in human HIF-2α) within the oxygen-dependent degradation domain (ODD) of HIF-α. Prolyl-hydroxylation by prolyl-4-hydroxylases and binding to pVHL are absolutely required for the execution of HIF proteolysis under normoxia (for a review on this topic, see Ref. 112). During hypoxia, prolyl-hydroxylases are inactive and HIF-α degradation is inhibited. In cell culture, HIF-α-subunits typically accumulate when oxygen concentrations fall below 5% (55). Three major mammalian HIF prolyl-hydroxylases have been identified, i.e., prolyl-hydroxylase domain (PHD)1, PHD2, and PHD3, all of which are expressed in renal epithelial cells and glomeruli, as shown by immunohistochemical methods (117). Inhibition of PHD results in increased HIF target gene expression even under severe hypoxia or in certain cell lines that are unable to degrade HIF-α (122).

A second hypoxic switch operates in the COOH-terminal transactivation domain of HIF-α with the hydroxylation of an asparagine residue. During hypoxia, asparagine hydroxylation is blocked and CBP/p300 recruitment is facilitated, enabling increased levels of transcription (Fig. 1). Factor-inhibiting HIF (FIH) hydroxylates the asparagine residue at position Asn803 in human HIF-1α, which corresponds to asparagine Asn851 in human HIF-2α. FIH is expressed in renal tubular epithelial cells and glomeruli, as shown by immunohistochemical methods (117). Inhibition of FIH results in increased HIF target gene expression even under severe hypoxia or in certain cell lines that are unable to degrade HIF-α (122).

Besides hypoxic activation, a nonhypoxic increase in HIF transcriptional activity has been shown to be mediated by nitric oxide and TNF-α (111), interleukin 1 (45, 121), angiotensin II (99), and a variety of growth factors including epidermal growth factor, insulin, and insulin-like growth factors (28, 54, 121, 129, 142). Nitric oxide, ROS, and certain oncogenes such as...
angiogenesis, erythropoiesis and iron homeostasis, cell migration, and cell-cell and cell-matrix interactions. Factors that are directly regulated by HIF and have relevance to the pathogenesis of acute and chronic kidney diseases include heme oxygenase-1 (HO-1), VEGF, plasminogen activator inhibitor-1 (PAI-1), tissue inhibitor of metalloproteinase-1 (TIMP-1), connective tissue growth factor (CTGF), EPO, Wilms’ tumor suppressor (WT-1), and others (112, 136) (Fig. 2) (see HIF SIGNALING AND RENAL INJURY).

**MOUSE MODELS OF DEFECTIVE HIF SIGNALING**

Tissue hypoxia occurs not only under pathological conditions but also during normal embryogenesis under physiological conditions, indicating an important role for HIF in development. In fact, inactivation of either HIF-1α, HIF-2α, HIF-β, or the VHL tumor suppressor in the murine germ line results in embryonic or perinatal lethality. Mice homozygously deficient for HIF-1α die in utero between embryonic (E) days 8 and 11 from neural tube defects, cardiovascular malformations, and increased cell death in the cephalic mesenchyme associated with tissue hypoxia (52, 105). HIF-β (ARNT)-deficient mice are not viable beyond E10.5 and die from defective vasculogenesis of the yolk sac and branchial arches (76). Different phenotypes have been published for HIF-2α germ line knockout mice, most likely reflecting variations in genetic background. Most HIF-2α homozygous knockout mice die in utero or perinatally unless bred as heterozygotes in a C57/BL6J and 129S6/SvEv background (113). HIF-2α-deficient mice lead to problems with catecholamine synthesis in the organ of Zuckerkandl, resulting in heart failure and midgestational death (128); 2) had problems with VEGF-mediated lung mat-
HIF IN KIDNEY FUNCTION

Invited Review

Hypoxia occurs physiologically during embryogenesis, and stabilization of HIF-α-subunits has been demonstrated during nephrogenesis in vitro and in vivo (8, 31). However, the exact role of HIF signaling in renal development is largely unexplored. To date, a developmental phenotype in the kidney has not been described for either pVHL or HIF knockout mice. Although the role of HIF signaling in renal development is unclear, HIF-α-subunits exhibit a cell type- and stage-specific expression pattern during nephrogenesis. This correlated with the expression of important angiogenic factors, such as VEGF and endoglin, supporting the notion that HIF signaling has a regulatory role in the developing kidney (8). HIF-1α expression was predominantly found in the cortical and medullary collecting ducts, S-shaped bodies, and glomerular cells (8). The expression of HIF-2α was detectable in podocytes, as well as in cortical and medullary endothelial and interstitial cells, but was absent in the fully developed kidney (8, 31). Furthermore, a distinct role for HIF-1α and HIF-2α in glomerular development has been proposed based on the finding that S- or comma-shaped bodies expressed only HIF-1α, whereas more mature glomeruli expressed HIF-2α (8). Although these studies support the notion that hypoxia plays a functional role during nephrogenesis, mechanistic insights from in vitro studies and from genetic approaches with conditional knockout mice are currently pending and are needed to define the role of individual HIF transcription factors during renal development.

HIF AND ERYTHROPOIESIS

In the regulation of erythropoiesis, the kidney serves as the most important physiological oxygen sensor and responds to systemic hypoxia with a rapid increase in EPO production by renal interstitial fibroblast-like cells (for recent reviews on the regulation and tissue expression of EPO, see Refs. 27 and 53). Other tissues, such as the liver, also have the capacity to produce EPO in an oxygen-dependent manner. However, nonrenal EPO production in the setting of end-stage renal disease is not able to compensate for the loss of renal EPO, resulting in anemia that requires treatment with systemically administered recombinant EPO. Although HIF-1 was initially identified as the factor that induces EPO during hypoxia, we and others have proposed that HIF-2 is the more important regulator of hypoxic EPO induction in hepatocytes and retinal cells (85, 93, 135). It is also likely that HIF-2 has the same dominance in renal EPO-regulation, as HIF-2α expression in the kidney colocalizes with EPO-producing renal interstitial fibroblast-like cells (103, 114). However, to provide a definitive answer, genetic studies are needed that compare the functional

Fig. 3. Consequences of von Hippel-Lindau (VHL) gene inactivation in the kidney. Renal cyst development in mice with inactivation of pVHL in proximal renal tubule cells using the PEPCK-Cre transgene (95) is shown. A: macroscopically visible renal cysts in a pVHL-deficient kidney (white arrows). B: multiple renal cysts lined by cuboidal, eosinophilic epithelial cells. Hematoxylin and cosin stain, magnification ×200. C: glomerular cyst development in pVHL-deficient kidneys. Shown is a glomerular cyst (*) with the glomerular tuft located at the cyst basis. Studies with the ROSA26-lacZ Cre-reporter indicated recombination activity in Bowman’s capsule, suggesting that Bowman's capsule of this cyst is pVHL deficient. Hematoxylin and cosin stain, magnification ×200.
consequences of HIF-2α vs. HIF-1α ablation in renal interstitial cells.

The ability of cells to efficiently target HIF-α for proteasomal degradation under normoxia is essential for normal erythropoiesis and has clinical importance with regard to EPO production. Patients with congenital Chuvash polycythemia are homozygous for a specific mutation in the VHL tumor suppressor commonly found at amino acid position Arg200 (Arg200Trp) (5, 90). Chuvash patients have raised red blood cell (RBC) counts from increased EPO production as a result of elevated HIF activity; however, they do not develop the tumors that are typically seen in patients with VHL disease, such as CNS hemangioblastomas, renal cell cancer of the clear cell type, and pheochromocytomas (36). Furthermore, mutations in PHD2, the most abundant PHD protein, result in a rare form of familial polycythemia from the inability to properly degrade HIF-α under normoxia (92).

In mice, we have shown that inactivation of pVHL in hepatocytes results in polycythemia due to an increase in hepatic HIF-2α (42, 94). In this model, pVHL was inactivated in a subset of hepatocytes and resulted in a 20- to 40-fold increase in serum EPO levels that was associated with profound elevation of hemoglobin values and RBC counts (93). In contrast to the liver, EPO production in kidneys from mutant mice was suppressed, as expected. Simultaneous inactivation of pVHL and HIF-1α did not change hemoglobin or RBC values, whereas simultaneous inactivation of pVHL and HIF-2α restored erythropoiesis to normal levels (93, 94), illustrating the importance of HIF-2 in hypoxic EPO regulation.

More importantly, our results support the notion that inhibition of HIF-α degradation in nonrenal tissues is sufficient to substantially raise systemic EPO levels and thus may be useful for the treatment of anemia. Indeed, pharmacological targeting of HIF-α degradation by prolyl-hydroxylase inhibition increased serum EPO levels in humans (71) and improved anemia of chronic disease and inflammation in animal models (69). In the latter studies, inhibition of HIF-α hydroxylation not only increased serum EPO levels but also improved iron uptake and metabolism. This is not surprising, as transferrin and its receptor had been previously found to be direct transcriptional targets of HIF (73, 100, 124). Interestingly, inhibition of prolyl-hydroxylation also resulted in a suppression of hepatic hepcidin, which is known to occur during hypoxia or in the presence of anemia, suggesting a role for HIF in its regulation. Hepcidin inhibits iron transport in the intestinal epithelium, the placenta, and macrophages through its effects on ferroportin protein stability, thus negatively impacting iron metabolism. It is upregulated during inflammation and is a key factor in the development of anemia of chronic disease (for recent reviews, see Refs. 30 and 33). Inhibition of prolyl-hydroxylation therefore has the potential to be a powerful pharmacological tool for the treatment of anemia in general and, in particular, anemia that is refractory to treatment with EPO.

HIF SIGNALING AND RENAL INJURY

HIF-α stabilization has been demonstrated in vivo in several acute and chronic renal injury models (57, 68, 81, 101–103, 125–127, 137, 139). While acutely injured kidneys appear to benefit from the protective effects of HIF-regulated biological processes, chronic hypoxia, mediated in part through HIF-1, can contribute to increased extracellular matrix production and epithelial-to-mesenchymal transition (EMT), thereby potentially promoting renal fibrosis and the progression of renal disease. The following section summarizes recent data on the biological effects of increased HIF signaling during acute and chronic hypoxic renal injury.

Acute Hypoxic Injury

During acute renal ischemia when HIF-α proteolysis is inhibited, HIF-1α can be detected in the nucleus of renal tubular epithelial cells, where it dimerizes with HIF-1β to form transcriptionally active HIF-1. In contrast, HIF-2α is undetectable in this cell type but is strongly expressed in renal interstitial fibroblasts and endothelial cells, supporting the notion that HIF-1 is the key mediator of hypoxic HIF signaling in nontransformed renal epithelia (101–103, 137, 139). As a global regulator of cellular adaptation to hypoxia, HIF regulates critical biological processes important for the survival of acutely hypoxic cells, such as anaerobic glycolysis (Pasteur effect), protein translation, cellular proliferation, and apoptosis. The role of HIF in the regulation of mitochondrial signaling, hypoxic cell death, and recovery from ischemia-reperfusion injury is controversial and most likely dependent on the cell type examined and the experimental conditions used (for a recent discussion on this topic, see Refs. 10, 37, and 44). Genetic studies with conditional knockout mice, for example, showed that HIF-1-deficient rodent brains (neuron-specific knockout) can either be protected from (46) or become more susceptible to (19) cerebral ischemic injury depending on the experimental model used, supporting the notion that “cytoprotective” effects of HIF-1 may be context dependent.

With regard to acute ischemic renal injury, we have shown that when glucose availability is limited, HIF-1 regulates the onset of hypoxia-induced cell death through its effects on glucose uptake and metabolism (10). Under hypoxic conditions, HIF-1-competent cells demonstrated increased glucose uptake and consumption, due to upregulation of glucose transporters and glycolytic enzymes, resulting in faster depletion of glucose resources and thus earlier cell death compared with HIF-1-deficient cells. We furthermore found that HIF-1, in the presence of glucose, was not required for renal epithelial cell survival under hypoxia and did not play a role in the execution of hypoxia-mediated cell death (10). Nevertheless, the role of HIF-1 in acute ischemia-reperfusion injury in vivo may be different. In vivo studies with kidney-specific HIF-1α conditional knockout mice are currently ongoing in our laboratory to address this question.

Despite its controversial role in acute hypoxic cell death, HIF-1 is known to upregulate factors that have been shown to be cytoprotective in hypoxic renal injury, including VEGF (59, 61), HO-1 (4, 49, 84, 133), and EPO (132). Pretreatment of rodents with a HIF prolyl-hydroxylase inhibitor (7, 38) or cobalt chloride (68, 81, 125), a chelating agent known to inhibit HIF-α proteolysis, resulted in improved glomerular filtration rate after ischemia and in models of acute nephrotoxic and glomerular injury associated with hypoxia, providing evidence that HIF-1 signaling is involved in “ischemic preconditioning” of the kidney, as has been proposed for other organs (14, 96). Although it is unclear at the moment which signaling
pathways and which renal cell types mediate this protective effect, inhibition of HIF prolyl-hydroxylation may be a powerful strategy in improving clinical outcome of ischemia-reperfusion injuries.

**Chronic Hypoxic Injury**

Chronic hypoxia has long been thought to be a major factor in the progression of chronic renal diseases irrespective of the underlying cause (29), as renal “scarring” is associated with loss of microvasculature. Moreover, recent work has suggested that discrepancies between oxygen demand and supply can even occur “early” in diseased kidneys before visible scarring is detected (82). Work by our laboratory and others supports the notion that HIF signaling could potentially promote the development of renal fibrosis by at least three mechanisms: 1) direct regulation of fibrogenic factors and synergy with transforming growth factor-β1 (TGF-β1), which is a potent profibrotic factor; 2) its potential role in EMT; and 3) its role in inflammation. In contrast to its potential profibrotic role, HIF may also have a protective function through its pro-angiogenic and cytoprotective effects under certain chronic renal disease conditions (126, 127, 139).

**HIF and profibrotic gene expression.** Hypoxia induces collagen I, decreases matrix-metalloproteinase 2, and increases TIMP-1 in renal epithelial cells (89). Hypoxia can also act synergistically with TGF-β1 in the regulation of certain hypoxia-responsive genes such as VEGF (108), endoglin (109), and EPO (110). Synergistic effects between hypoxia and TGF-β1 have furthermore been demonstrated with regard to the production of collagens (26, 107). These observations and the finding that several genes which play critical roles in renal fibrogenesis are direct HIF-1 targets [e.g., TIMP-1 (88), PAI-1 (60), CTGF (47)] suggest that increased HIF activity is likely to play an important role in the pathogenesis of tubulointerstitial fibrosis through direct transcriptional regulation of specific profibrotic genes and/or through enhancement of TGF-β1 signaling. Synergistic interaction between SMAD3, a downstream effector of TGF-β1, and HIF-1 has been suggested by Sanchez-Elsner et al. (108) as a possible mechanism in the transcriptional regulation of VEGF. Although a direct role for HIF has yet to be demonstrated, hypoxia also increases SMAD3 mRNA levels and promotes the thrombospondin-dependent release of latent TGF-β, thus activating TGF-β signaling (143). Whereas the concept of direct regulation of profibrotic genes by HIF-1 is straightforward and consistent with the canonical hypoxia response, the interplay of HIF-1 and TGF-β signaling appears to be complex and is more difficult to understand.

**HIF and EMT.** Elegant in vivo studies have shown that EMT contributes significantly to the development of renal fibrosis (58). EMT is characterized by the disassembly of intercellular contacts, such as E-cadherin adherens junctions, leading to cell-cell separations associated with an increase in motility and reorganization of the actin cytoskeleton. This eventually results in the generation of fibroblast-like cells that express mesenchymal markers and display increased motility and invasive-ness (58). We and others have shown that hypoxia increased the percentage of transitioned renal epithelial cells in a HIF-dependent fashion in vitro and in vivo (48, 62, 78), supporting a role for HIF-1 in the dedifferentiation and transition of renal epithelial to mesenchymal fibroblast-like cells. The observation that hypoxia, through HIF, influences the differentiation state of cells has also been made in other biological systems (1, 2, 21, 22, 86, 123, 140). Although the underlying molecular mechanisms may differ between cell types, an increase in Notch signaling as a result of direct biochemical interaction between HIF-1α and the Notch ICD may be one of the mechanisms by which cells are maintained in an undifferentiated state, as has been suggested by Gustafsson et al. (39). How important this interaction will be for the hypoxic induction of EMT in the context of renal fibrosis remains to be investigated.

**HIF and inflammation.** A third mechanism by which HIF may impact the pathogenesis of tubulointerstitial disease is through the regulation of inflammatory responses. Microenvironmental changes, such as hypoxia, strongly impact inflammatory cell recruitment (66) and function (23). Elegant studies with tissue-specific HIF knockout mice showed that HIF-1 is essential for myeloid cell-mediated inflammation mainly through its effects on cellular ATP generation. Inactivation of HIF-1 resulted in a profound impairment of myeloid cell aggregation, motility, and invasiveness, whereas forced expression of HIF-1 had the opposite effect (66). Furthermore, hypoxia and HIF-1 in lymphocytes have been shown to modulate lymphocytic function and T cell receptor signaling (15, 63, 87, 115). Thus, given these observations, it is easy to conceive that alterations in HIF signaling in inflammatory cells may also play a significant role in renal inflammation and subsequent fibrosis and thus in the progression of chronic renal disease.

**HIF and Renal Cancer**

The most common form of kidney cancer is renal cell cancer of the clear cell type (CC-RCC). A molecular hallmark of sporadic CC-RCC and hereditary CC-RCC associated with the von Hippel-Lindau familial tumor syndrome are mutations in the VHL tumor suppressor pVHL. Loss of pVHL function results in oxygen-independent HIF-α stabilization, increased HIF transcriptional activity, and constitutive upregulation of HIF target genes. While patients with sporadic CC-RCC are characterized by somatic inactivation of both VHL gene copies in renal epithelial cells, patients with the VHL tumor syndrome transmit germ line mutations of the VHL gene. VHL patients are predisposed to develop an autosomal dominant familial tumor syndrome that follows Knudson’s two-hit hypothesis (loss of the remaining wild-type allele in tumors). VHL disease is characterized by the development of highly vascularized, benign and malignant neoplasms in multiple organs. Typical disease manifestations include renal cysts, which sometimes can mimic autosomal dominant polycystic kidney disease (18), renal cell carcinomas, hemangioblastomas of the retina and central nervous system, and pheochromocytomas (74). Although the highly vascular nature of VHL-deficient tumors is easily explained by increased VEGF production as a result of increased HIF transcriptional activity, VHL-associated renal carcinogenesis is more difficult to understand and most likely requires multiple other genetic events in addition to loss of pVHL function. Besides regulating the degradation of HIF-α subunits, pVHL has been shown to have additional biological functions, which may or may not be critical for renal tumorigenesis (41).
Aside from a regulatory role in tumor angiogenesis, HIF plays a key role in the regulation of factors that are important for the development and invasiveness of CC-RCC. These include, among others, TGF-α, a potent renal epithelial mitogen, cell cycle regulator cyclin D1 (CCND1), and chemokine receptor CXCR4 (11, 97, 116, 119, 138, 141). With regard to the individual contribution of HIF-1 and HIF-2 to renal tumor development, it is of interest that a substantial number of VHL-defective CC-RCC cell lines do not express HIF-1α, but express HIF-2α (83). This is in contrast to normal, nontransformed renal epithelial cells, in which HIF-2α is not detectable during ischemia (103). A bias toward HIF-2α expression was also found in clinical CC-RCC samples (130). Thus VHL-associated tumor development may depend on a shift in the ratio of HIF-1α vs. HIF-2α levels toward an increase in HIF-2α. In support of this hypothesis, VHL-reconstituted 786-O CC-RCC cells transfected with a nondegradable form of HIF-2α were still able to form tumors in nude mice, thereby overriding pVHL’s tumor suppressor function (65). By contrast, expression of nondegradable HIF-1α in a similar experimental setting did not have a tumor-promoting effect (80). Consistent with these findings, inactivation of HIF-2α by RNA interference suppressed tumor formation in a VHL-deficient background (64, 145). Taken together, these reports suggest that HIF-1 and HIF-2 have diverse functions with regard to VHL renal tumorigenesis. HIF-2 has been proposed to preferentially regulate signaling pathways critical for renal cell growth, such as signaling through the TGF-α/epidermal growth factor receptor pathway and through cell cycle regulator cyclin D1 (11, 97, 116, 138, 141). In addition to VHL-associated CC-RCC, HIF-α stabilization can be found in renal cell cancers that are associated with mutations of the tuberous sclerosis tumor suppressor TSC-2 (72) and in rare leiomyomatosis-associated renal cancers. The latter form of renal cancer is characterized by fumarate hydratase deficiency, the inability to convert fumarate to malate, which results in HIF prolyl-hydroxylase inhibition; fumarate acts as a competitive inhibitor of HIF prolyl-hydroxylation (51) (Fig. 1). Whether an increase in HIF-1 and HIF-2 activity in these rare forms of renal cancer has the same biological effects as in VHL-negative CC-RCC is unclear and awaits further investigation.

SUMMARY

In this review, I have summarized the most recent findings in HIF signaling and have tried to provide the reader with a perspective on how recent advances in HIF biology may affect our understanding of renal development and disease, including renal cancer. This review was by no means intended to cover all possible aspects of HIF biology in the kidney, but instead it focuses on selected areas that have high potential for impacting current concepts of pathogenesis and treatment of kidney diseases. The reader is furthermore provided with an appreciation of the broad spectrum of cell type- and context-dependent effects of canonical and noncanonical HIF signaling, which in certain settings can be quite contrasting (e.g., its proapoptotic vs. its antiapoptotic effects). In keeping with this notion, HIF’s beneficial cytosectopic effect in acute ischemia-reperfusion injury is contrasted to its role in inflammation and its potentially profibrotic role in chronic renal hypoxia, which needs further study. These considerations are particularly important with regard to pharmacological inhibition of HIF prolyl-hydroxylases, which offers enormous potential for the treatment of anemia and acute hypoxic injuries. Rigorous investigations of HIF’s effects on metabolism, inflammation, cell growth, and differentiation are therefore required before this treatment strategy can be safely exploited in clinical practice.

ACKNOWLEDGMENTS

I thank the National Cancer Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Kidney Foundation, and the American Heart Association for supporting the work in the laboratory. Furthermore, I thank Mangatt Biju, Debra Higgins, Michael Madaio, and Erin Rankin for a critical reading of the manuscript.

DISCLOSURES

To remain within the scope of this review, I have limited the number of references and apologize to those colleagues whose original work was not cited. In those cases, the reader is referred to selected review articles.

REFERENCES

No natural text is available for this document.


